Showing results (1-10 of 341) with videos related to
Sort By:
Pageof 35
Pharmacology & Therapeutics|January 1, 1990
Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529)M D Green, P Alderton, J Gross, et al.Investigational New Drugs|January 1, 1986
Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trialH S Hochster, M D Green, R H Blum, et al.Investigational New Drugs|August 1, 1990
Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancerM D Green, J L Speyer, J C Wernz, et al.Critical Reviews in Oncology/Hematology|January 1, 1991
New anthracycline antitumor antibioticsF M Muggia, M D GreenThe American Journal of Medicine|April 1, 1985
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breastJ L Speyer, M D Green, N Dubin, et al.Cancer Research|March 1, 1986
Synergistic activity of doxorubicin and the bisdioxopiperazine (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187) against the murine sarcoma S180 cell lineS Wadler, M D Green, F M MuggiaBiochemical Pharmacology|May 1, 1987
Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitroS Wadler, M D Green, R Basch, et al.Cancer Treatment Reports|February 1, 1983
Repeated femoral vein cannulation for administration of chemotherapeutic agentsB D Nidus, J L Speyer, J Bottino, et al.Cancer Investigation|January 1, 1989
Phase I/II trial of thymostimulin in opportunistic infections of the acquired immune deficiency syndromeA Chachoua, M D Green, F Valentine, et al.American Journal of Clinical Oncology|December 1, 1984
Phase II trial of cyclophosphamide and cis-platinum for non-small cell bronchogenic carcinomaA M Schmidt, R H Blum, M Clayton, et al.Pageof 35